Cardiol Therapeutics Files 6-K Report
Ticker: CRDL · Form: 6-K · Filed: Nov 18, 2024 · CIK: 1702123
Sentiment: neutral
Topics: sec-filing, 6-K, reporting
Related Tickers: CRDL
TL;DR
Cardiol Therapeutics (CRDL) filed a 6-K, includes a news release. Watch for updates.
AI Summary
Cardiol Therapeutics Inc. filed a Form 6-K on November 18, 2024, reporting for the month of November 2024. The filing includes Exhibit 99.1, which is a news release. The company is incorporated in Canada and its principal executive offices are located in Oakville, Ontario.
Why It Matters
This filing indicates ongoing reporting activity for Cardiol Therapeutics Inc., which is relevant for investors tracking the company's regulatory compliance and public disclosures.
Risk Assessment
Risk Level: low — This is a routine filing (Form 6-K) that primarily serves as a reporting mechanism for foreign private issuers and does not contain significant new financial or operational information.
Key Players & Entities
- Cardiol Therapeutics Inc. (company) — Registrant
- November 18, 2024 (date) — Filing Date
- Oakville, Ontario, Canada (location) — Principal Executive Offices
- 001-40712 (other) — SEC File Number
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information which the issuer makes or is required to make public in its home country or to distribute or publish in its home country.
What is included in this specific 6-K filing?
This filing includes Exhibit 99.1, which is a news release.
When was this Form 6-K filed?
This Form 6-K was filed on November 18, 2024.
Where are Cardiol Therapeutics Inc.'s principal executive offices located?
Cardiol Therapeutics Inc.'s principal executive offices are located at 602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5.
Does Cardiol Therapeutics Inc. file annual reports under Form 20-F or Form 40-F?
Cardiol Therapeutics Inc. indicates it files annual reports under Form 20-F.
Filing Stats: 226 words · 1 min read · ~1 pages · Grade level 13.9 · Accepted 2024-11-18 11:39:33
Filing Documents
- form6k.htm (6-K) — 6KB
- exhibit99-1.htm (EX-99.1) — 18KB
- exhibit99-1xu001.jpg (GRAPHIC) — 8KB
- 0001062993-24-019238.txt ( ) — 35KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CARDIOL THERAPEUTICS INC. (Registrant) Date: November 18, 2024 By: /s/ Chris Waddick Chris Waddick Title: Chief Financial Officer